Bentley Systems Releases Open-Source Library: iModel.js
17.10.2018 11:58:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced the initial release of its iModel.js library, an open-source initiative to improve the accessibility, for both visualization and analytical visibility, of infrastructure digital twins. iModel.js can be used by developers and IT professionals to quickly and easily create immersive applications that connect their infrastructure digital twins with the rest of their digital world. iModel.js is the cornerstone of Bentley’s just-announced iTwin™ Services that combine iModelHub, reality modeling, and web-enabling software technologies within a Connected Data Environment (CDE) for infrastructure engineering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005008/en/
Bentley Systems Releases Open-Source Library: iModel.js.(Photo: Business Wire)
Bentley’s iModels have become a de facto standard for visibility into digital engineering models. iModelHub manages an iModel as a distributed database with an intrinsic ledger of changes—enabling alignment, accountability, and accessibility of its digital components—to form the backbone of an infrastructure digital twin.
The iModel.js library is a comprehensive collection of JavaScript packages that build on the most open, popular, and flexible standards for modern cloud and web development. It is written in TypeScript, and leverages open technologies including SQLite, Node.js, NPM, WebGL, Electron, Docker, Kubernetes, and of course HTML5 and CSS. The same codebase can produce cloud services and web, mobile, and desktop applications. The source code is hosted on GitHub and is distributed under the MIT license.
With iModel.js, it is simple to create a web-based experience that shows interactive “nD” views (1D, 2D, 3D, 4D, etc.) of iModels that are assembled and synchronized from BIM files and other digital engineering models, and from data created directly with iModel.js. Those same views can also include digital (reality) context, real-time sensor data, and other data from enterprise sources and analytics. Since the iModel is synchronized by iModelHub, it always reflects the most recent updates from all project participants, who are thus able to visualize and analyze changes between points in time or between versions. Importantly, only users and applications authorized by the iModel owner, through iModelHub, are granted access through iModel.js.
Johan Palm, program manager – Digital Project Delivery at Hatch, said, “iModel.js gives Hatch the ability to implement a stakeholder engagement technology that extends the iModelHub visionary technology. We can expose complex project information to a level that is accessible, consumable, and extendable via the cloud and in context to the 3D model. Most importantly we can do so in a manner that embraces change as the project progresses. iModel.js aligns with Hatch’s internal development strategies as it is built on modern, highly portable web technology. Bentley is a key software technology partner on Hatch projects globally where our main objective is to provide a positive impact to our client’s assets and operations.”
Cai Chengguo, chair and general manager, Shenzhen Expressway Consulting Group, said, “The digital twin powered by iModelHub is efficiently improving project management, substantially reducing the waste of resources caused by site problems and will achieve digital handover after completion of the project for visual operations and maintenance.”
Keith Bentley, Bentley Systems’ founder and CTO, said, “We firmly believe that iModel.js, and of course the foundation upon which it is built, is the most open, productive, intuitive, and powerful development environment for capital projects and infrastructure assets, ever. We’re excited to work with user organizations, strategic partners, and third-party developers to build an open ecosystem around iModels to tap the vast potential of infrastructure digital twins. With iModel.js, the well-refined techniques of mainstream cloud and web development can leverage the physical and virtual reality in digital twins with near-zero impedance. By open-sourcing the libraries we use to create our iTwin™ cloud services, we expect to foster a substantial and vibrant ecosystem of innovation.”
More about iModel.js: iModeljs.org.
More about iModels and iModelHub: iModelHub.com.
About Bentley Systems
Bentley Systems is the leading global
provider of software solutions to engineers, architects, geospatial
professionals, constructors, and owner-operators for the design,
construction, and operations of infrastructure. Bentley’s MicroStation-based
engineering and BIM applications, and its digital twin cloud services,
advance the project delivery (ProjectWise) and the asset
performance (AssetWise) of transportation and other public works,
utilities, industrial and resources plants, and commercial and
institutional facilities.
Bentley Systems employs more than 3,500 colleagues, generates annual
revenues of $700 million in 170 countries, and has invested more than $1
billion in research, development, and acquisitions since 2012. From
inception in 1984, the company has remained majority-owned by its five
founding Bentley brothers. Bentley shares transact by invitation on the
NASDAQ Private Market; strategic partner Siemens AG has accumulated a
non-voting minority stake
www.bentley.com
Bentley, the Bentley logo, AssetWise, Connected Data Environment, iTwin, MicroStation, and ProjectWise are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005008/en/
Contact information
Press:
Bentley Systems
Jennifer Maguire
+1 610 458 2695
jennifer.maguire@bentley.com
Follow
us on Twitter: @BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom